Moringa

Metadata

Approved Indications

European Regulatory Bodies

Moringa oleifera has not been assessed by any of the three major European phytotherapy regulatory bodies:

• Commission E (Germany): No monograph exists. Moringa was never part of the European herbal tradition evaluated by Commission E during its 1978-1994 assessment period.
• ESCOP: No monograph. Moringa is entirely outside the scope of European scientific cooperative assessment, which focuses on herbs with established European use.
• EMA/HMPC: No assessment report, community herbal monograph, or community list entry. Moringa oleifera is not listed in the HMPC work program or the EU herbal substances inventory.

This absence reflects the geographic and cultural boundaries of the European regulatory framework rather than any negative evaluation of the plant’s merit. The European system was designed around European and Mediterranean phytotherapy traditions, and tropical plants with primarily Ayurvedic or African traditional use are structurally difficult to accommodate.

Indian Pharmacopoeia and Ayurvedic Recognition

• Ayurvedic Pharmacopoeia of India (API): Moringa oleifera is listed as Shigru in the Ayurvedic Pharmacopoeia of India. The dried root bark is indicated for goitre (galaganda), glycosuria (prameha), and lipid disorders (medoroga). Dried seeds are also recognized for lipid disorders. Leaf, seed, root bark, and stem bark are indicated for internal abscess (vidradhi), piles (arsha), and fistula-in-ano (bhagandara).
• Ayurvedic Classification: Shigru is classified as having katu (pungent) and tikta (bitter) rasa, laghu (light) and ruksha (dry) guna, ushna (hot) virya, and katu (pungent) vipaka. It is primarily kapha-vata shamaka (pacifying kapha and vata doshas).
• Classical References: Documented in the Charaka Samhita and Sushruta Samhita as a medicinal plant. Acharya Charaka classifies Shigru as Svedopaga (aids perspiration) and Krimighna (anthelmintic). The Rigveda contains early references to the plant as a domestic species. A literature survey has identified 149 formulations in 145 dosage forms of Shigru recommended across 24 disease categories in classical Ayurvedic texts.

FSSAI (India)

• Moringa leaf powder is approved as a food ingredient and is included in nutraceutical formulations regulated by the Food Safety and Standards Authority of India (FSSAI).

United States

• Dietary supplement: Widely available as a dietary supplement under DSHEA (1994). Not evaluated by the FDA for any specific disease claims.
• GRAS status: Moringa oleifera leaf has self-affirmed GRAS (Generally Recognized as Safe) status for use as a food ingredient in certain commercial applications.

WHO Recognition

• The World Health Organization (WHO) has recognized Moringa oleifera as a significant plant for nutritional applications in developing countries, particularly for addressing micronutrient deficiencies and childhood malnutrition in tropical regions.

Agreement/Disagreement

There is a notable disconnect between Moringa’s strong recognition in Indian/Ayurvedic pharmacopoeial systems and its complete absence from European regulatory frameworks. Unlike herbs such as turmeric (which has at least entered the European regulatory conversation), moringa remains almost entirely outside the European phytotherapy paradigm. The WHO recognition of its nutritional value represents an intermediate position — acknowledging the plant’s importance without making specific therapeutic claims. The nutritional density of moringa leaves is well-established and not seriously contested; the disagreement lies in the degree to which specific therapeutic claims (antidiabetic, anti-inflammatory, immunomodulatory) can be supported by clinical evidence.

Conditions Treated

Primary (Moderate Evidence)

• Nutritional supplementation and micronutrient deficiency — The most robust evidence base for moringa. Dried moringa leaf powder provides approximately 25 g protein per 100 g (with all essential amino acids), 1475 mg calcium per 100 g, 1752 mg potassium per 100 g, and significant amounts of iron, vitamin A (beta-carotene), vitamin C, and B-complex vitamins. Multiple intervention studies in developing countries document improvements in hemoglobin, ferritin, and nutritional markers in malnourished populations. A study in anemic women of reproductive age demonstrated statistically significant increases in both hemoglobin and ferritin levels with moringa leaf powder supplementation compared to controls.

• Anti-inflammatory support — Preclinical evidence is strong for NF-kB pathway inhibition and Nrf2 activation by moringa isothiocyanates. A double-blind RCT (n=73) in metabolic syndrome patients showed that 1000 mg moringa extract daily for 8 weeks significantly reduced high-sensitivity C-reactive protein (hs-CRP). However, a separate 12-week DBRPCT (n=65) in prediabetic patients using 2.4 g/day dried leaf powder found no significant effects on serum inflammatory markers (CRP, MCP-1, TNF-alpha, IL-1beta, IL-6). Results remain mixed, and the discrepancy may relate to differences in extract preparation, dosing, patient populations, and bioavailability of active constituents.

Secondary (Preliminary Evidence)

• Blood glucose management — The most actively researched clinical application. A parallel-group RCT in type 2 diabetic subjects in Nigeria showed significant reductions in fasting blood glucose with moringa leaf supplementation over 40 days. A 30-day RCT (n=240) using 500 mg moringa capsules twice daily reported a significant reduction in fasting blood glucose from 187.3 mg/dL to 132.6 mg/dL in the intervention group versus a non-significant decrease in controls. A 3-month unblinded RCT in Sahrawi women with type 2 diabetes also reported enhanced glycemic control with moringa leaf powder. However, a 2025 meta-analysis of RCTs with GRADE assessment found no significant pooled effects on HbA1c or fasting plasma glucose, though postprandial glucose was modestly improved. The meta-analysis concluded that current evidence does not support consistent cardiometabolic benefits, and heterogeneity across studies was substantial.

• Lipid modulation — Several small RCTs report improvements in total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol in diabetic or metabolic syndrome patients. Subgroup analyses from the 2025 meta-analysis suggested potential significant improvements in triacylglycerols based on dosage, intervention duration, and participant age. HDL-C increased in participants under 50 years, while those 50 years and older and those receiving 10 g/day or more experienced significant reductions in certain lipid parameters. However, overall pooled evidence remained inconclusive with very low certainty by GRADE criteria.

• Immunomodulation (HIV/AIDS adjunct) — A systematic review and meta-analysis of seven publications involving 1,022 HIV-positive participants evaluated moringa supplementation effects on immune function and BMI. Clinical studies demonstrated that moringa improved CD4 counts and nutritional status in HIV-positive patients and improved immunological and hematological parameters in patients on highly active antiretroviral therapy (HAART). However, the quality of included studies was variable, and moringa was used as a nutritional adjunct rather than a replacement for antiretroviral therapy.

Traditional (Ayurvedic Uses — Shigru/Sahajan)

• Vata disorders (Vata vyadhi): Joint pain, muscle stiffness, and neurological conditions — Shigru is classified as a primary Vata-pacifying herb. External application of bark paste is traditional for joint inflammation. The Ayurvedic rationale is consistent with modern anti-inflammatory mechanisms (NF-kB inhibition, COX modulation).
• Skin diseases (Kustha/Kandu): Topical use of leaf paste or bark preparations for dermatological conditions including itching, eczema, and wounds. Antimicrobial and wound-healing properties have some preclinical support.
• Worm infestation (Krimi): Traditional anthelmintic use, particularly of the bark and seeds. Preclinical studies confirm antiparasitic activity of moringa seed extracts.
• Poison/toxin management (Visha): Shigru is classified as a Vishagna (antidote) in several classical texts. This likely relates to its hepatoprotective and antioxidant properties rather than direct antidote activity.
• Urinary calculi (Ashmari): Traditional use of root bark preparations for kidney stones and urinary disorders.
• Inflammation and swelling (Sopha): Both internal and topical preparations for inflammatory conditions, supported by modern understanding of its anti-inflammatory pharmacology.
• Nasal therapy (Nasya karma): Seed preparations used in traditional nasal administration for sinusitis and respiratory conditions.
• Sweating therapy (Sveda): Leaf preparations used to promote diaphoresis in febrile conditions.

Mechanism of Action

Primary Mechanisms

1. Isothiocyanate-mediated Nrf2 activation: The glucosinolate glucomoringin, abundant in moringa leaves, is enzymatically hydrolyzed by myrosinase upon tissue damage (chewing, processing) to release the isothiocyanate moringin (4-(alpha-L-rhamnosyloxy)benzyl isothiocyanate, also designated MIC-1). Moringin directly interacts with Kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm by modifying critical cysteine residues. This disrupts the Keap1-Nrf2 complex, allowing the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) to translocate to the nucleus. In the nucleus, Nrf2 binds to antioxidant response elements (AREs) in the promoter regions of cytoprotective genes, upregulating expression of phase II detoxification enzymes including NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), and glutamate-cysteine ligase catalytic subunit (GCLC). Downstream effects include reduction of reactive oxygen species (ROS) in both mitochondria and cytoplasm. This mechanism is analogous to, though structurally distinct from, sulforaphane from broccoli — both are isothiocyanates that activate Nrf2, but moringa isothiocyanates are uniquely stable solids due to ring glycosylation.

2. NF-kB pathway inhibition: Moringin simultaneously suppresses the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling pathway. In LPS-stimulated macrophages, MIC-1 decreased nuclear accumulation of NF-kB while increasing nuclear Nrf2. The cross-talk between Nrf2 activation and NF-kB suppression is bidirectional — Nrf2 activation inhibits NF-kB translocation, reducing production of pro-inflammatory cytokines including TNF-alpha, IFN-alpha, IL-1beta, and IL-6. In a murine sepsis model, oral administration of MIC-1 (80 mg/kg) significantly reduced expression of inflammatory markers in liver, kidney, spleen, and colon and decreased spleen weight, demonstrating systemic anti-inflammatory efficacy.

3. Flavonoid-mediated antioxidant activity: Quercetin and kaempferol, the dominant flavonoids in moringa leaves (quercetin present at approximately 100 mg/100 g of dried leaves as quercetin-3-O-beta-D-glucoside), exert potent antioxidant effects through direct free radical scavenging, metal chelation (particularly iron and copper), and inhibition of pro-oxidant enzymes. Quercetin also inhibits lipid peroxidation and enhances endogenous antioxidant enzyme activity. Kaempferol contributes additional anti-inflammatory effects through inhibition of COX-2 and iNOS expression.

Secondary Mechanisms

4. Chlorogenic acid metabolic effects: Chlorogenic acid, a major phenolic acid in moringa leaves, inhibits glucose-6-phosphatase in the liver (reducing hepatic glucose output) and enhances glucose uptake in peripheral tissues by modulating GLUT4 translocation. It also inhibits alpha-glucosidase in the intestinal brush border, slowing carbohydrate digestion and absorption. These combined mechanisms provide a pharmacological basis for the observed blood glucose-lowering effects in clinical studies.

5. Beta-sitosterol cholesterol modulation: Beta-sitosterol, a phytosterol present in moringa leaves, reduces intestinal cholesterol absorption by competing with dietary cholesterol for incorporation into mixed micelles. It also modulates hepatic cholesterol metabolism by upregulating LDL receptor expression through sterol regulatory element-binding protein (SREBP) pathways. This mechanism, well-established for phytosterols generally, contributes to the lipid-lowering effects observed in clinical trials.

6. Immunomodulatory activity: Moringa leaf extracts demonstrate bidirectional immunomodulation. In immunocompromised states (such as HIV infection or chemotherapy-induced immunosuppression), moringa supplementation enhances CD4+ T-cell counts, natural killer cell activity, and immunoglobulin production. In inflammatory states, the Nrf2/NF-kB crosstalk suppresses excessive pro-inflammatory signaling. Zeatin (a cytokinin present in moringa leaves) may contribute to immune cell proliferation, though this mechanism is less well-characterized than the isothiocyanate and flavonoid pathways.

7. Niazimicin anti-tumor activity: Niazimicin, a thiocarbamate present in moringa leaves, has demonstrated anti-tumor promoting activity in preclinical models by inhibiting Epstein-Barr virus early antigen activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). This represents a mechanism distinct from direct cytotoxicity — instead modulating tumor promotion pathways. Clinical relevance remains entirely preclinical.

Key Pharmacological Note

Moringa’s therapeutic profile arises from a multi-constituent, multi-target system rather than any single dominant mechanism. The convergence of isothiocyanate-mediated Nrf2/NF-kB modulation, flavonoid antioxidant activity, chlorogenic acid metabolic effects, and phytosterol lipid modulation produces a broad pharmacological profile that addresses oxidative stress, inflammation, and metabolic dysregulation simultaneously. This polypharmacological nature complicates standardization efforts — unlike herbs where a single compound class dominates (e.g., curcuminoids in turmeric), moringa’s activity depends on the interplay of structurally diverse compounds across multiple chemical classes. The bioavailability of moringin is notably better than many other plant isothiocyanates due to its glycosylated structure, which enhances aqueous solubility and stability.

Clinical Evidence Summary

Clinical evidence for moringa consists of multiple small RCTs, several systematic reviews, and one comprehensive meta-analysis with GRADE assessment (2025). While no single large, definitive trial exists, the aggregate evidence is moderately supportive for glycemic control and nutritional supplementation, with more mixed results for inflammatory markers and lipid endpoints.

Key Randomized Controlled Trials

Systematic Reviews and Meta-Analyses

• Stohs and Hartman (2015): Comprehensive review of safety and efficacy published in Phytotherapy Research. Concluded that moringa leaf extracts exhibit the greatest antioxidant activity among plant parts studied, that various animal safety studies indicate a high degree of safety, and that no adverse effects were reported in human studies. Noted the need for additional human studies using standardized extracts. [Source: Phytother Res. 2015;29(6):796-804]

• Meta-analysis of cardiometabolic outcomes with GRADE (2025): The most rigorous assessment to date. Included RCTs with a minimum 2-week duration assessing moringa supplementation in adults. Found no significant pooled effects on HbA1c, fasting plasma glucose, or any lipid outcome. Postprandial glucose and blood pressure were modestly improved. Subgroup analyses suggested potential significant improvements in triacylglycerols by dosage, duration, and age. GRADE assessment reduced certainty of evidence to very low for all evaluated outcomes due to risk of bias, substantial heterogeneity, indirectness, and methodological limitations. The meta-analysis concluded that “current evidence does not support consistent cardiometabolic benefits of moringa supplementation in adults.” [Source: Nutrients. 2025;17(22):3501]

• Umbrella review of inflammatory diseases (2025): Reviewed 26 systematic reviews of moringa’s effects on inflammatory diseases. Found that TNF-alpha was evaluated in approximately 31% of included studies. Concluded that despite promising biological potential, the translation into clinical practice has not yet been achieved, evidenced by the scarcity of approved clinical trials. [Source: Front Pharmacol. 2025;16:1572337]

• Systematic review of HIV supplementation (2025): Meta-analysis of 7 publications (8 studies, n=1,022) evaluating moringa supplementation in adults living with HIV. Demonstrated improvements in CD4 counts, BMI, and nutritional biomarkers. Moringa was well-tolerated within commonly used dosage ranges. [Source: Front Nutr. 2025;12:1667158]

• Blood glucose scoping review (Taweerutchana et al., 2020): Scoping review of the literature on moringa and blood glucose levels. Found consistent trends toward glucose reduction across heterogeneous study designs, but noted wide variability in preparations, dosing, and study quality. [Source: PubMed PMID: 32444043]

Evidence Limitations

• Sample sizes are generally small (n=30-240 across individual studies), with the majority under 100 participants.
• Heterogeneity in preparations is a major confounding factor: studies use whole leaf powder, aqueous extracts, ethanolic extracts, and capsule formulations at widely varying doses (500 mg to 8 g/day).
• Lack of standardization — no agreed-upon active marker compound or standardization parameter for clinical studies.
• Most studies originate from Nigeria, India, and other tropical developing countries, introducing potential geographic and dietary confounding.
• Several studies have inadequate blinding, unclear randomization procedures, or lack intention-to-treat analysis.
• The 2025 GRADE meta-analysis rated all cardiometabolic outcomes as very low certainty, indicating that the true effect may be substantially different from the estimated effect.
• Publication bias cannot be excluded, particularly for studies published in regional journals.
• No long-term efficacy or safety studies beyond 3 months in controlled settings.

Safety Profile

General Assessment

Moringa oleifera has a favorable safety profile supported by extensive dietary use across tropical regions. Millions of people consume moringa leaves, pods, and seeds as a regular food source. Animal toxicology studies demonstrate a high safety margin: the LD50 of an ethanol extract of moringa leaves in mice was greater than 6.4 g/kg, and no adverse reactions were observed at single doses up to 5000 mg/kg or repeated doses up to 1000 mg/kg for 14 days in rats, with no histopathological findings. The Stohs and Hartman (2015) review confirmed that no adverse effects were reported in association with human studies.

Contraindications

• Concurrent antidiabetic medication: Moringa has demonstrated blood glucose-lowering effects in multiple clinical studies. Concurrent use with insulin, metformin, sulfonylureas, or other antidiabetic agents may potentiate hypoglycemic effects. Blood glucose monitoring is essential, and dose adjustments of conventional medication may be required.
• Hypothyroid conditions: Animal studies suggest that Moringa oleifera may inhibit the conversion of thyroxine (T4) to triiodothyronine (T3). This creates a theoretical interaction with levothyroxine and a potential exacerbation of hypothyroid symptoms. Patients with thyroid disorders should consult their healthcare provider before using moringa. Some moringa plant parts (particularly seeds) contain goitrogenic compounds, though the clinical significance at typical supplemental doses of leaf preparations is uncertain.
• Autoimmune conditions: As with all immunomodulatory herbs, theoretical concern exists about stimulating autoimmune pathways. This is a general precaution rather than a documented adverse effect.
• Pre-surgical: Discontinue at least 2 weeks before elective surgery due to potential blood glucose-lowering and mild anticoagulant effects.

Drug Interactions

• Antidiabetic drugs (metformin, sulfonylureas, insulin): Additive hypoglycemic effect. The most clinically relevant interaction. Blood glucose monitoring is required with concurrent use.
• Levothyroxine and thyroid medications: Animal evidence suggests potential inhibition of T4 to T3 conversion. Monitor thyroid function tests if moringa is used concurrently with thyroid hormone replacement.
• Antihypertensive medications: Some clinical evidence suggests mild blood pressure-lowering effects. Additive hypotension is theoretically possible, though clinically significant interactions have not been documented.
• CYP450 substrates: In vitro studies demonstrate that moringa leaf extracts inhibit CYP1A2 (IC50 = 13.8 mcg/mL), CYP3A4 (IC50 = 52.5 mcg/mL), CYP2D6, and CYP2E1 in a dose-dependent manner. However, an in vivo pharmacokinetic study in HIV-infected adults demonstrated that moringa leaf powder did not significantly affect the pharmacokinetics of nevirapine (a substrate of CYP2C9, CYP2D6, and CYP3A5). The discrepancy between in vitro inhibition and in vivo effects suggests limited clinical relevance at typical supplemental doses, though caution is warranted with narrow therapeutic index drugs metabolized by CYP3A4 or CYP1A2.
• Anticoagulants/antiplatelets: Theoretical interaction based on some antiplatelet activity observed in preclinical studies. No clinical case reports, but caution is reasonable.
• Nevirapine and antiretroviral drugs: Despite the in vivo study showing no significant pharmacokinetic effect on nevirapine, other data suggest that moringa may increase the serum concentration of nevirapine. Until further clarification, monitoring is advised. Moringa may decrease serum concentrations of amodiaquine (antimalarial).
• Overall drug interaction risk: LOW-MODERATE. In vitro enzyme inhibition data are concerning, but in vivo human data are reassuring for at least some drug substrates. The antidiabetic interaction is the most clinically meaningful.

Side Effects (at Recommended Doses)

• Common: Generally very well-tolerated. Mild gastrointestinal symptoms (nausea, bloating, loose stools, diarrhea) may occur, particularly at higher doses (greater than 7 g/day of leaf powder). These tend to be mild and transient.
• Uncommon: Insomnia has been reported in some users. Temporary appetite changes.
• Rare: Isolated case reports of cutaneous toxicity (including one case of Stevens-Johnson syndrome and one of cutaneous toxicity with respiratory distress and tongue edema) have been documented following moringa powder consumption. These appear to be idiosyncratic allergic/hypersensitivity reactions rather than dose-dependent toxicity.
• Of note: No significant hepatotoxicity or nephrotoxicity signals have emerged from clinical studies, though some preclinical data suggest potential alterations in liver and kidney function at very high doses.

Reproductive Safety

• Pregnancy (Category C): Recent studies propose that ingestion of moringa before, during, and after pregnancy may lead to adverse fetal developmental outcomes, potentially by causing contraction of the uterine wall. Animal studies support anti-fertility and abortifacient effects at high doses. Insufficient human pregnancy safety data exist. Moringa should be avoided during pregnancy until adequate safety data are available. Women of childbearing potential should be informed of these concerns.
• Lactation: Moringa is traditionally used in some cultures to promote lactation (galactagogue), and limited studies have explored this application. However, systematic safety assessment during lactation is insufficient. Consult a healthcare provider before use during breastfeeding.
• Fertility: Animal studies suggest potential anti-fertility effects including anti-spermatogenic activity at high doses. Relevance to human fertility at typical supplemental doses is unknown but warrants caution in individuals actively trying to conceive.

Toxicology

• Oral LD50 in mice: greater than 6.4 g/kg for ethanolic leaf extract.
• No overt toxicity at single oral doses up to 5000 mg/kg in rats.
• No adverse effects at repeated doses of 1000 mg/kg/day for 14 days in rats.
• No significant histopathological findings in subchronic toxicity studies.
• Moringa seed extract has shown higher toxicity potential than leaf extracts in some models — the safety profile described here pertains primarily to leaf preparations.
• Root and bark preparations contain alkaloids (moringine, moringinine) with potential neurotoxic properties at high doses; these plant parts should be used with greater caution than leaf preparations.

Clinical Dosage

Dried Leaf Powder

• Standard nutritional dose: 2-6 g/day (approximately 1-3 teaspoons), mixed into food, water, or smoothies
• Therapeutic dose range (clinical trials): 2.4-8 g/day in divided doses
• Upper tolerance limit: Up to 70 g of fresh leaves per day (equivalent to approximately 11 teaspoons of dried powder), though gastrointestinal symptoms may increase above 7 g/day of powder
• Note: The wide dose range across clinical trials (500 mg to 8 g/day) reflects lack of standardization and dosing consensus

Capsules/Extracts

• Typical capsule dose: 400-500 mg per capsule, 2-6 capsules daily (800-3000 mg/day total)
• Concentrated extract: 500-1000 mg/day of standardized leaf extract
• Metabolic syndrome protocol: 1000 mg/day of extract (based on the DBRPCT showing hs-CRP reduction)
• Antidiabetic protocol: 500 mg twice daily (based on the n=240 glycemic control trial)

Traditional Ayurvedic Preparations

• Shigru kwatha (decoction): Bark decoction prepared by boiling 10-20 g of bark in 200 mL water, reduced to 50 mL; taken twice daily
• Churna (powder): 3-6 g of leaf powder per day in divided doses with warm water or honey
• Svarasa (fresh juice): 10-20 mL of fresh leaf juice
• External use: Bark paste applied topically for joint pain and skin conditions

Duration of Use

• Clinical trials have assessed durations from 30 days to 3 months without significant safety concerns.
• Traditional use in food contexts supports long-term daily consumption.
• For therapeutic applications, a minimum of 4-8 weeks is recommended before evaluating efficacy.
• No established upper limit for duration of use as a food supplement, though periodic reassessment is prudent for therapeutic applications.

Special Population Considerations

• Malnourished children and pregnant/lactating women in developing countries: Many intervention studies use moringa specifically in these populations as a nutritional supplement. Dosing in these contexts should follow locally established protocols and healthcare provider guidance.
• HIV-positive patients: Studies have used moringa as a nutritional adjunct to antiretroviral therapy. It should never replace standard antiretroviral treatment.

Sources

• Stohs SJ, Hartman MJ. Review of the Safety and Efficacy of Moringa oleifera. Phytother Res. 2015;29(6):796-804. doi:10.1002/ptr.5325
• Afiaenyi IC, Ngwu EK, Okafor AM, Ayogu RNB. Effects of Moringa oleifera leaves on the blood glucose, blood pressure, and lipid profile of type 2 diabetic subjects: A parallel group randomized clinical trial of efficacy. J Hum Nutr Diet. 2025;38(1):e13318. doi:10.1177/02601060231176873
• Meta-analysis: Effects of Moringa oleifera Lam. Supplementation on Cardiometabolic Outcomes: A Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. Nutrients. 2025;17(22):3501
• Sailaja BS, Arunachalam R, Basu M, et al. Moringa oleifera leaf extract on glycemic control and inflammation in metabolic syndrome: a randomized controlled trial. J Complement Integr Med. 2025
• Waterman C, Rojas-Silva P, Tumer TB, et al. Isothiocyanate-Rich Moringa oleifera Extract Reduces Weight Gain, Insulin Resistance, and Hepatic Gluconeogenesis in Mice. Mol Nutr Food Res. 2015;59(6):1013-1024
• Kim Y, Wu AG, Jaja-Chimedza A, et al. Moringa isothiocyanate-1 regulates Nrf2 and NF-kB pathway in response to LPS-driven sepsis and inflammation. PLoS One. 2021;16(4):e0248691. doi:10.1371/journal.pone.0248691
• Mundkar M, Bijalwan A, Soni D, Kumar P. Neuroprotective potential of Moringa oleifera mediated by NF-kB/Nrf2/HO-1 signaling pathway: A review. J Food Biochem. 2022;46(12):e14451. doi:10.1111/jfbc.14451
• Jaja-Chimedza A, Graf BL, Simmler C, et al. Moringa isothiocyanate activates Nrf2: potential role in diabetic nephropathy. AAPS J. 2017;19(3):717-726. PMC6647035
• Taweerutchana R, Lumlerdkij N, Vannasaeng S, Akarasereenont P, Sriwijitkamol A. The effects of Moringa oleifera on blood glucose levels: A scoping review of the literature. Complement Ther Med. 2020;49:102375. PMID: 32444043
• Leone A, Spada A, Battezzati A, Schiraldi A, Aristil J, Bertoli S. Moringa oleifera Seeds and Oil: Characteristics and Uses for Human Health. Int J Mol Sci. 2016;17(12):2141
• Anwar F, Latif S, Ashraf M, Gilani AH. Moringa oleifera: a food plant with multiple medicinal uses. Phytother Res. 2007;21(1):17-25. PMID: 17089328
• Abd Rani NZ, Husain K, Kumolosasi E. Moringa Genus: A Review of Phytochemistry and Pharmacology. Front Pharmacol. 2018;9:108. doi:10.3389/fphar.2018.00108
• Vergara-Jimenez M, Almatrafi MM, Fernandez ML. Bioactive Components in Moringa Oleifera Leaves Protect against Chronic Disease. Antioxidants. 2017;6(4):91. PMC5745501
• Brilhante RSN, Sales JA, Pereira VS, et al. Research advances on the multiple uses of Moringa oleifera: A sustainable alternative for socially neglected population. Asian Pac J Trop Med. 2017;10(7):621-630
• Tumer TB, Rojas-Silva P, Poulev A, Raskin I, Waterman C. Direct and indirect antioxidant activity of polyphenol- and isothiocyanate-enriched fractions from Moringa oleifera. J Agric Food Chem. 2015;63(5):1505-1513
• Kushwaha S, Chawla P, Kochhar A. Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (Moringa oleifera) against CYP3A4 and CYP2D6 isozymes. Phytomedicine. 2019;65:153091. PMID: 31301970
• Kasolo JN, Bimenya GS, Ojok L, et al. Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. J Med Food. 2010;13(6):1313-1318. PMID: 19745507
• Prabsattroo T, Wattanathorn J, Iamsaard S, Muchimapura S, Thukhammee W. Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS Res Ther. 2017;14:12. PMC5348890
• Mahajan SG, Banerjee A, Chauhan BF, Padh H, Nivsarkar M, Mehta AA. Inhibitory effect of n-butanol fraction of Moringa oleifera Lam. seeds on ovalbumin-induced airway inflammation in a guinea pig model of asthma. Int J Toxicol. 2009;28(6):519-527
• The Ayurvedic Pharmacopoeia of India. Part I. Government of India, Ministry of AYUSH
• WHO. Moringa oleifera: nutritional use and medicinal applications. WHO Regional Office reports on neglected medicinal plants

Connections

• Compare with astragalus: Both are immune-supporting herbs from non-European traditions (Ayurveda and TCM respectively) with extensive traditional documentation but limited Western clinical evidence and no European regulatory monographs. Both demonstrate bidirectional immunomodulatory activity and face the same evidence translation gap.
• Compare with holy basil (tulsi): Fellow Ayurvedic herb with C-rated evidence and similar regulatory absence in Europe. Both show metabolic benefits (blood glucose, lipids) in small RCTs. Holy basil acts primarily through HPA axis modulation and eugenol COX-2 inhibition, whereas moringa acts primarily through Nrf2 activation and NF-kB inhibition — complementary anti-inflammatory mechanisms that might be synergistic.
• Compare with turmeric/curcumin: Both are Ayurvedic-origin anti-inflammatory herbs with NF-kB inhibition as a shared mechanism. Turmeric has a considerably larger clinical evidence base and has entered the European regulatory conversation, while moringa remains outside it. Both face bioavailability challenges — curcumin due to poor absorption, moringin due to variable glucosinolate-to-isothiocyanate conversion.
• Compare with elderberry: Both classified under immune support with immunomodulatory and anti-inflammatory properties. Elderberry has more focused clinical evidence (acute viral URI) while moringa has broader but less focused evidence across nutritional, metabolic, and immune endpoints.
• Moringa’s Nrf2 activation mechanism parallels the cytoprotective pathways studied in cruciferous vegetable research (sulforaphane from broccoli), positioning it within the broader isothiocyanate phytochemistry framework rather than solely within Ayurvedic pharmacology.
• The nutritional density of moringa leaves represents a distinct value proposition not shared by most other herbs in this collection — it functions simultaneously as a food, nutritional supplement, and potential therapeutic agent, a combination that challenges conventional categorical distinctions in phytotherapy.